Behandeling van huidafwijkingen bij doelgerichte medicijnen in de oncologie

In recent years new targeted agents have been developed for the treatment of malignancies, including inhibitors of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (receptor) (VEGF(R)), mammaliantarget of rapamycin (mTOR) and BRAF. These inhibitors frequently cause skin toxicity. Treatment of skin toxicity is important to ensure continued treatment with the targeted agent and improve quality of life. However, there are no 'evidence based guidelines' for treatment of the skin toxicity. In this article we provide an overview of the recent literature, a description of the most common adverse effects of the skin, hairs, nails and eyes and the therapeutic options to best treat these adverse events.